NVA237 meets Phase IIb endpoint

Sosei (Tokyo:4565) said NVA237 met the primary endpoint of trough forced expiratory volume at one second (FEV1) in a European Phase IIb trial to treat chronic obstructive pulmonary disease (COPD). The...